Zensar Technologies Limited has received in-principle approval from its Board of Directors for the merger of two US-based step-down subsidiaries into its material wholly owned subsidiary, Zensar Technologies Inc. The Board meeting held on July 29, 2026, authorized the consolidation of Bridgeview Life Sciences LLC and M3BI LLC into the parent US entity, either directly or indirectly through a new entity. This restructuring aims to drive business synergies, enhance operational efficiencies, and unify control over operations across its North American footprint.

The merger involves entities engaged in providing digital solutions and technology services to global organizations. As per the disclosure made pursuant to Regulation 30(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with the SEBI Master Circular dated January 30, 2026, the merging entities will cease to exist as separate step-down subsidiaries post-merger. The transaction does not constitute a related-party transaction under Regulation 23(5)(b) of the SEBI Listing Regulations, as it involves wholly owned subsidiaries within the group structure.

Financial details of the entities involved in the merger, based on standalone figures for the year ended March 31, 2026, highlight the scale of the integration. Zensar Technologies Inc., the surviving entity, reported a net worth of $74.66 million and turnover of $326.96 million. The merging entities contribute additional scale, with M3BI LLC reporting a net worth of $9.32 million and turnover of $46.8 million, while Bridgeview Life Sciences LLC reported a net worth of $0.4 million and turnover of $4.74 million.

The Board noted that there will be no change in the shareholding pattern of Zensar Technologies Limited consequent to this merger. Since the transaction is internal to the group’s US operations, no cash consideration or share exchange ratio is applicable. The proposal will now be considered separately by the Boards and shareholders of the respective merging entities and Zensar Technologies Inc., USA.

Strategic Rationale

The primary driver for this consolidation is the pursuit of greater business synergies and higher operational efficiencies. By merging Bridgeview Life Sciences LLC and M3BI LLC into Zensar Technologies Inc., the company seeks to streamline management structures and ensure unified control of operations. This structural simplification is expected to reduce administrative overheads and improve decision-making agility in the US market, where all three entities operate in the digital solutions and technology services sector. The move reflects a broader trend among IT services firms to optimize their global subsidiary structures for better governance and cost efficiency.

Zensar Technologies reported consolidated revenue of ₹15,083 million ($159.5 million) for the quarter ended June 30, 2026, marking an 8.9% year-on-year increase and a 4.0% quarter-on-quarter rise in INR terms. The Pune-based IT services firm posted a net profit of ₹1,838 million ($19.4 million), up 1% from ₹1,820 million in Q1FY26. However, profitability metrics faced pressure, with EBITDA margins contracting by 150 basis points sequentially to 14.6%, primarily due to transition costs associated with early-stage execution of large new deals.

The results were approved by the Board of Directors on July 29, 2026, and reviewed by statutory auditors S R B C & Co LLP pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. In constant currency terms, revenue grew by 1.1% sequentially but declined by 2.0% year-on-year, reflecting the impact of foreign exchange fluctuations. The company maintained a strong balance sheet with net cash and cash equivalents of $317.5 million, a 0.6% increase year-on-year.

Segment Performance

Banking and Financial Services (BFSI) emerged as the primary growth engine, contributing 48.8% of total revenue. The vertical registered an 8.3% quarter-on-quarter and 14.7% year-on-year growth in constant currency terms. Conversely, other verticals faced headwinds. Telecommunication, Media and Technology (TMT) revenue declined by 28.0% year-on-year in constant currency, while Healthcare and Life Sciences (HLS) fell by 8.7%. Manufacturing and Consumer Services (MCS) also saw a 3.4% year-on-year decline.

Geographically, the US region accounted for 66.2% of revenue, growing 2.5% sequentially but declining 3.7% year-on-year in constant currency. Europe contributed 21.5% of revenue, with a 3.0% year-on-year growth in constant currency despite a 1.4% sequential decline. Africa’s contribution stood at 12.3%, showing minimal change with a 0.8% year-on-year decline.

What the Numbers Show

A notable divergence exists between top-line growth and margin expansion. While revenue grew sequentially, EBITDA dropped by 8.6% to $23.3 million. Management attributed this to a 200-basis point impact from large deal transitions and higher direct costs for travel, visas, and training. This suggests that recent wins, particularly in AI-driven projects, are currently cost-intensive during the mobilization phase.

Client concentration remains stable, with the top 20 clients contributing 56.6% of revenue, slightly up from 56.0% in Q4FY26. The number of clients generating over $10 million in revenue increased to 19 from 15 in the previous quarter, indicating deeper engagement with key accounts. Operating expenses as a percentage of revenue improved to 15.1% from 16.5% in Q4FY26, demonstrating some operational leverage despite the margin pressure from direct costs.

Strategic Wins and Outlook

Zensar secured several significant AI-focused wins in Q1FY27, including grants lifecycle modernization for a leading US property insurer and payments optimization for a global energy leader. CEO Manish Tandon highlighted broad-based volume gains despite a challenging macroeconomic environment characterized by prolonged decision cycles. CFO Pulkit Bhandari noted that these large deals strengthen positioning for high-value strategic programs.

The company also reported improved human capital metrics, with total headcount rising to 11,342 from 10,779 in FY26. Voluntary attrition decreased to 9.6% from 9.8% in the previous period, and utilization rates improved to 85.1%. Zensar was recognized as a Leader in Everest Group’s Guidewire Services PEAK Matrix Assessment 2026 and ranked #1 in IT Services in Great Place to Work’s ‘Best Companies to Work For 2026’.